We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Mrs
Teresa
Young
teresa.young2@nhs.net
Mrs
Teresa
Young
teresa.young2@nhs.net
Tara
Chalk
tara.chalk@nhs.net
More information about this study, what is involved and how to take part can be found on the study website.
Malignant neoplasms of ill-defined, secondary and unspecified sites
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Cancer diagnosis/treatment results in unwanted symptoms/toxicity so assessing the risks and benefits of new treatments requires knowledge of both effectiveness against the cancer and impact on quality of life. Several research groups, including the EORTC, have developed questionnaires to measure quality of life so that patients can be monitored and their treatment side effects investigated. These groups are now looking to enhance the use of their questionnaires more efficiently. It would be helpful to pool results from studies using different questionnaires investigating the same symptoms, but because the questions on each questionnaire are subtly different, this is not easy.
In this study patients complete several widely used similar questionnaires. Their scores are then compared with those from the EORTC questionnaires.
Using statistical analysis we will produce an algorithm (mathematical equation) 'converting' scores between questionnaires. The algorithm could be useful in clinical research when two groups of researchers are investigating a new drug with a side effect of fatigue but are using different questionnaires to assess this e.g EORTC Fatigue Scale versus FACT Fatigue Scale. The algorithm will link the scores by ‘predicting’ the score on one questionnaire using the score on the other. The two studies can then be compared, or their results pooled, giving a larger sample for analysing any effect.
Using other statistics we will compare all the questionnaires and see how good (or not) they are at detecting symptoms (validity and reliability) and how sensitive they are to changes over time as the symptoms worsen or improve . Knowing which are the most sensitive questionnaires for different domains of quality of life and side effects is critical because fewer patients would then need to be recruited in future research.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Validation of outcome measures;
You can take part if:
You may not be able to take part if:
Cross-sectional sample 1. Patients with brain metastases 2. Patients with serious cognitive impairment 3. Patients participating in other competing quality of life studies 4. Poor literacy skills - inability to read and understand the PIS, consent and questionnaires which will only be available in English. Longitudinal Sample: 1. Previous chemotherapy 2. Patients not having chemotherapy or whose chemotherapy has already commenced. 3. Patients with brain metastases 4. Patients with serious cognitive impairment 5. Patients participating in other competing quality of life studies 6. Poor literacy skills - inability to read and understand the PIS, consent and questionnaires which will only be available in English. Survivorship Sample: 1. Patients with brain metastases 2. Patients with serious cognitive impairment 3. Participating in other competing quality of life studies 4. Poor literacy skills - inability to read and understand the PIS, consent and questionnaires which will only be available in English. 5. Patients currently on treatment
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Mrs
Teresa
Young
teresa.young2@nhs.net
Tara
Chalk
tara.chalk@nhs.net
Mrs
Teresa
Young
teresa.young2@nhs.net
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by EAST AND NORTH HERTFORDSHIRE NHS TRUST and funded by European Organisation for Research and Treatment of Cancer .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 42386
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
